Drug intelligence / Profile preview

K1.1

Development stage: Preclinical
Lead developer: Sunshine Biopharma
Modality: Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Small Molecules
Administration: Intravenous

Overview

K1.1 is an experimental drug candidate referenced in preclinical research for oncology, specifically hepatocellular carcinoma (HCC). According to available information, "K1.1/LNP" refers to a formulation of the agent K1.1 delivered via lipid nanoparticles (LNPs). In animal models, repeated systemic dosing of K1.1/LNP was found to reduce the growth of two different types of human HCC tumors orthotopically grafted into mice[8]. The precise mechanism of action, molecular target(s), and chemical structure have not been disclosed in public sources as of June 2025.

Brand names: K1.1 mRNAK-1.1 mRNAK 1.1 mRNA
Other names: K1.1 mRNAK-1.1 mRNAK 1.1 mRNA

Targets

TF (Transferrin)

Beyond the preview

Go deeper on K1.1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on K1.1.

Explore the full profile